KINASE INHIBITORS
Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)
This retrospective review, which compared the risk of cardiotoxicity associated with third-generation EGFR-TKI osimertinib versus all other drugs and versus other EGFR-TKIs, found that the reporting odds ratios for cardiac failure, QT prolongation, and atrial fibrillation were higher among patients receiving osimertinib versus other EGFR-TKIs.
JACC: CardioOncology
